Inhibrx, Inc. Common Stock
INBX
INBX was delisted on the 29th of May, 2024.
102 hedge funds and large institutions have $512M invested in Inhibrx, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 12 closing their positions.
72% more capital invested
Capital invested by funds: $297M → $512M (+$215M)
70% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 27
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 100 → 102 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
97% less call options, than puts
Call options by funds: $369K | Put options by funds: $12.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$27.2M |
| 2 |
PA
Perceptive Advisors
New York
|
+$17.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.6M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$6.56M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$18.5M |
| 2 |
Millennium Management
New York
|
-$8.12M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.36M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.36M |
| 5 |
SCM
Sio Capital Management
New York
|
-$4.14M |
INBX Hedge Fund Activity: Q3 2022 in Review
102 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q3 2022, worth a combined $512M — up 72% from $297M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new INBX positions and 12 closed out — a net gain of 2 holders — while 46 added to existing stakes and 27 trimmed.
The largest buyer was State Street, adding an estimated $27.2M. The largest seller was Capital World Investors, exiting entirely with an estimated $18.5M sold.
- 102 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q3 2022, up from 100 in Q2 2022.
- Funds reported $512M of Inhibrx, Inc. Common Stock stock for Q3 2022, up 72% quarter-over-quarter.
- 14 funds opened new Inhibrx, Inc. Common Stock positions in Q3 2022 and 12 closed out, a net change of +2 holders.
- The largest Inhibrx, Inc. Common Stock buyer in Q3 2022 was State Street, an estimated $27.2M added.
- The largest Inhibrx, Inc. Common Stock seller in Q3 2022 was Capital World Investors, an estimated $18.5M sold.
Based on aggregated 13F filings for Q3 2022.